La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Merck Bilan de santé

Santé financière contrôle des critères 4/6

Merck possède un total de capitaux propres de $43.6B et une dette totale de $37.8B, ce qui porte son ratio d'endettement à 86.6%. Son actif total et son passif total sont $112.6B et de $69.0B. L'EBIT de Merck est $19.8B ce qui fait que son ratio de couverture des intérêts 20.7. Elle dispose de liquidités et de placements à court terme de $11.4B.

Informations clés

86.6%

Ratio d'endettement

US$37.79b

Dette

Ratio de couverture des intérêts	20.7x
Argent liquide	US$11.35b
Fonds propres	US$43.65b
Total du passif	US$68.98b
Total des actifs	US$112.63b

Mises à jour récentes de la santé financière

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Jul 18

Recent updates

Merck: Buy This Bargain Before It's Gone

Aug 12

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Jul 31

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MRK ( $38.2B ) dépassent ses passifs à court terme ( $26.1B ).

Passif à long terme: Les actifs à court terme de MRK ( $38.2B ) ne couvrent pas ses passifs à long terme ( $42.9B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de MRK ( 60.6% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de MRK a été réduit de 95.9% à 86.6% au cours des 5 dernières années.

Couverture de la dette: La dette de MRK est bien couverte par le flux de trésorerie opérationnel ( 44.2% ).

Couverture des intérêts: Les paiements d'intérêts de MRK sur sa dette sont bien couverts par l'EBIT ( 20.7 x couverture).

Merck Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Recent updates

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

First quarter dividend of US$0.77 announced

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck: Positive Developments, But Watch The Q2 Earnings

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck: Among The Best Health Care GARP Plays Today

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

First quarter dividend of US$0.77 announced

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Stock: Still Discounted To Graham P/E

Merck Announces Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines